Heidelberg Engineering has two new models in its family of multimodality ophthalmic imaging devices (Spectralis).
Vista, CA, and Heidelberg, Germany
-Heidelberg Engineering has two new models in its family of multimodality ophthalmic imaging devices (Spectralis). The latest models add laser autofluorescence technology (BluePeak) to the company’s spectral-domain optical coherence tomography devices.
The technology measures the metabolic activity of the retinal pigment epithelium, which would allow for the tracking of the progression of geographic atrophy in patients with dry age-related macular degeneration, according to a prepared statement.
“The [proprietary] imaging platform was designed to be modular,” said Carole McCallum, marketing manager for Heidelberg Engineering. “These new models demonstrate our ability to incorporate new imaging technology into our existing platform and offer clinicians more utility and value with the multimodality design.”
The company now offers seven imaging models; the laser autofluorescence is available on five of them. The main differences between the models are their imaging modalities, availability for wide-field imaging, and hardware upgrade options, according to the statement.